Why the study?
Because many traumatic conditions or pathologies cause cellular damage through ischemia-reperfusion syndrome, exploring new therapeutic alternatives such as adiponectin to reduce these lesions is relevant.
Key points are not available for this paper at this time.
Design
Literature review
May position adiponectin as a therapeutic target in ischemia-reperfusion; hypothesis-generating and requires prospective trials before clinical consideration.
Adiponectin, among other diverse adipokines, is produced in greater quantity and has an effect on the adipose tissue and other tissues in the body. Adiponectin plays three main roles: regulatory metabolic and sensitizing function of insulin in the liver and muscles; it acts as an anti-inflammatory cytokine and in vascular protection, besides important cardiac protection in the presence of ischemia-reperfusion syndrome. Since many situations resulting from traumatic accidents or pathologies are due to cell damage caused by ischemia-reperfusion syndrome, it is relevant to study new therapeutic alternatives that will contribute to reducing these lesions. The objective of this study is to carry out a literature review on the role of adiponectin in ischemia-reperfusion syndrome.
No takes yet. Share an insight, caveat, or question.
Carballo et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: